TRUE — On December 8, 2023, the FDA authorized Casgevy as the first CRISPR-based gene therapy approved in the United States Is Real
Verified on July 20, 2026
The FDA officially approved Casgevy on December 8, 2023, as the first CRISPR-based gene therapy authorized in the United States. FDA approves CASGEVY, the first CRISPR/Cas9 gene... - PMC.
How strongly independent, cited sources support this verdict.
Claim reviewed
On December 8, 2023, the FDA authorized Casgevy as the first CRISPR-based gene therapy approved in the United States.
Analysis summary
The FDA officially approved Casgevy on December 8, 2023, as the first CRISPR-based gene therapy authorized in the United States. This treatment was specifically cleared for patients with sickle cell disease.
Evidence profile
Key findings
- FDA approves CASGEVY, the first CRISPR/Cas9 gene ... - PMC.
- FDA Approves First Gene Therapies to Treat Patients with.
Sources
Analyzed across 2 independent publishers
Citations
Copy formatted citations from the verified sources above.
Need to verify another claim?
Open Claims Radar to analyze headlines, posts, or links with live source checks.
Verify a claim
Possum Mattern Studios